You are here

Levoleucovorin, a Folate Analog, Gets FDA Approval for Injection

Prevents Harmful Effects of Chemotherapy

The FDA has approved Levoleucovorin (Khapzory, Spectrum Pharmaceuticals, Henderson, Nevada) for injection for three indications:

  • rescue after high-dose methotrexate therapy in patients with osteosarcoma;
  • diminishing toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination; and
  • treatment for metastatic colorectal cancer in combination with fluorouracil.

Levoleucovorin is not indicated for the treatment of pernicious anemia and megaloblastic anemia secondary to lack of vitamin B12 as there is a risk of neurologic manifestations progressing, despite hematologic remission. Patients who have experienced severe hypersensitivity to leucovorin products, folic acid, or folinic acid should not use levoleucovorin.

Common adverse reactions in patients who received levoleucovorin rescue with high-dose methotrexate therapy included stomatitis (38%) and vomiting (38%). The most common adverse reactions in patients treated with levoleucovorin in combination with fluorouracil for metastatic colorectal cancer included stomatitis (72%), diarrhea (70%), and nausea (62%).

Spectrum expects to launch the drug in January 2019.

Source: Healio.com, October 23, 2018

Recent Headlines

Citrus, Berries, Broccoli Reduce Risk of Cancer and CVD
Changes in Antibiotic Recommendations for Children
Influences Gene Involved in Circadian Rhythms
‘The Perfect Drug for Trauma-Focused Psychotherapy’
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients